Accelmed

Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtech innovations.

Click Therapeutics, Inc. is a company that develops and commercializes digital therapeutics designed to address unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company focuses on software as prescription medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Click’s innovative Digital Therapeutics™ are intended for use independently or alongside traditional biomedical treatments. The company leverages its Clickometrics® adaptive data science platform to personalize user experiences, enhancing engagement and treatment outcomes. Following a successful clinical trial, its smoking cessation program is widely available across multiple payers and providers. Currently, Click is advancing its lead prescription program into a phase III clinical trial for the treatment of major depressive disorder in adults, further solidifying its position in the digital health space.

Keystone Dental was founded in March 2006, and aspires to build a market leading, global brand recognized within the dental community for its integrity, trust and commitment to improving the standard of care for patients and their quality of life. Since then, they have rapidly grown into a diversely skilled, fast-moving team of professionals committed to providing excellent customer service and producing high-quality products and services.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.

NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a short train of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California.

TearLab Corporation develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol TEAR and on the Toronto Stock Exchange under the symbol TLB.

BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CE marked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US.

Diagnostic Robotic develops a signal-agnostic artificial intelligence system for healthcare insurers, providers, and patients. It allows building powerful predictive analytics models that will solve a world-wide challenge, strained health budgets, and workforces. Diagnostic Robotic was founded on 2017 and is headquartered in Tel Aviv, Israel.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

Strata Skin Sciences is a medical technology company that specializes in dermatology and plastic surgery. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions; and the MelaFind® system used to assist in the identification and management of melanoma skin cancer.

Cogentix Medical products have increased treatment efficiency and lowered patient risk. Macroplastique® established the European market for bulking agents, EndoSheath® protective barrier redefined endoscopy and Urgent® PC set the standard for percutaneous tibial nerve stimulation (PTNS) as a treatment for Overactive Bladder. Cogentix Medical was formed in 2015 following a merger of Uroplasty and Vision-Sciences.

SoniVie is developing an advanced denervation solution to treat pulmonary hypertension.

Eximo Medical is an early stage Israeli company with a novel hybrid catheter technology for superior tissue resection invascular and gastrointestinal endoluminal applications. CatHI™, Eximo's proprietary single-use hybrid catheter, combines the best of the two leading technology solutions: optical fibers that deliver short laser pulse and a "blunt" mechanical knife.

Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.

EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009 and headquartered in Andover, Massachusetts.

CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.

Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.

EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

ValCare, Inc., a medical device company, designs and develops devices and accessories for minimally invasive treatment of heart valve disease. The company was founded in 2012 and is based in Irvine, California.

CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.

NLT SPINE, a clinical stage VC-backed company, specializes in the development and marketing of innovative Minimally Invasive Spinal Surgery (MISS) products for treating degenerative spinal conditions. The company's vision is to improve patient care by shifting from traditional open surgical routines to MISS, employing new methods and technologies to enhance safety, predictability and outcomes.

CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.

Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

Medical Compression Systems (MCS) Ltd. provides solutions for the prevention of deep vein thrombosis (DVT) and venous thromboembolism (VTE). The company’s product pipeline includes ActiveCare+S.F.T., a non-pharmaceutical mechanical solution that provides the prevention of DVT/VTE for in and out of hospital patient settings; and ActiveCare+DTx, which prevents DVT, as well as identifies proximal venous flow obstruction. Its product pipeline also comprises the ActiveCast, a device for bone fracture treatment; and the ActiveCare Vascular, a device used in the outpatient wound care market.

CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.